| چکیده انگلیسی مقاله |
Objectives: Renal fibrosis represents the principal pathological characteristic of diabetic nephropathy (DN). Quercetin, a well-known flavonoid with diverse pharmacological effects, has been studied for its link to preventing DN. Previous studies indicated that SIRT5 might have significant implications in fibrotic diseases. This study investigated whether the protective effects of quercetin on DN was related to SIRT5. Methods: Three doses of quercetin (30 mg/kg, 60 mg/kg, and 120 mg/kg) were orally administered to streptozotocin-induced diabetic rats over a period of four months. Colorimetric methods were used to measure blood urea nitrogen (BUN), serum creatinine (SCr) and urine creatinine (UCr). Enzyme-linked immunosorbent assay (ELISA) was used to quantify the level of urine microalbumin (Ualb). The ratio of urine microalbumin to urine creatinine (Ualb/UCr) was calculated. Periodic acid-Schiff (PAS) stain and Masson's trichrome stain were used to observe glycogen deposition and collagen accumulation in the renal cortex, respectively. Western blot, ELISA, and immunohistochemical stain were performed to quantify the levels of SIRT5 protein in kidneys of rats. Results: Diabetic rats exhibited increased levels of SCr, BUN, and Ualb/UCr, accompanied by significant glycogen deposition and collagen accumulation in renal cortex. These changes were associated with an increased level of SIRT5 protein. Following treatment of DN rats with varying doses of quercetin, all kidney function and pathology indices showed varying degrees of reversal, accompanied by a reduction in SIRT5 protein levels. Conclusion: Quercetin ameliorated renal fibrosis in DN rats via the inhibition of SIRT5, suggesting a novel mechanism of quercetin in the treatment of DN. |
| نویسندگان مقاله |
| Guangyu Ma
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
| Zhi Xu
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
| Yishu Zhang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
| Bingzheng Dong
Department of Urology, Xuzhou Central Hospital, The Affiliated School of Clinical Medicine of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China.
| Yunye Zhang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
| Xing Cheng
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China
| Jingqiu Cheng
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China
| Wei Sun
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
| Jianyun Wang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
|